BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Natalizumab

Progressive Multifocal Leukoencephalopathy (PML)

  • TYSABRI increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI [see Warnings and Precautions (5.1)].
  • Healthcare professionals should monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML. TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML. For diagnosis, an evaluation that includes a gadolinium-enhanced magnetic resonance imaging (MRI) scan of the brain and, when indicated, cerebrospinal fluid analysis for JC viral DNA are recommended [see Contraindications (4), Warnings and Precautions (5.1)]. Risk factors for the development of PML include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants.
  • Because of the risk of PML, TYSABRI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the TOUCH Prescribing Program [see Warnings and Precautions (5.2)] 

 


FDA and Industry Communications

Approved Risk Evaluation and Mitigation Strategies (REMS)

TYSABRI (Natalizumab) Injection

Patient Counseling Information

Medication Guides

Patient Medication Guide

Package Inserts

Natalizumab

Additional Information

Updated July 2020